Engstrom P F, Arnoult J B, Mazow M L, Prager T C, Wilkins R B, Byrd W A, Hofmann R J
Department of Ophthalmology, University of Texas Health Science Center at Houston.
Ophthalmology. 1987 Aug;94(8):971-5. doi: 10.1016/s0161-6420(87)33338-x.
The effectiveness of Botulinum toxin (Oculinum) therapy in 76 patients with the diagnosis of essential blepharospasm was analyzed. Botulinum offers relief to almost all patients suffering from essential blepharospasm, however, this relief is usually temporary. The response time for repeated treatments tended to be longer than the first treatment. Patients with mild blepharospasm responded significantly longer to Botulinum injection, than those with severe spasms. The response to Botulinum was not significantly different in patients with Meige syndrome than in patients with only essential blepharospasm. Patients previously treated surgically for essential blepharospasm did not respond differently than those patients with no previous surgical therapy. The authors believe that Botulinum toxin injection is an effective, although temporary, mode of therapy for the signs and symptoms of this focal dystonia. The authors recognize that there may be psychologic factors affecting the response.
分析了肉毒杆菌毒素(Oculinum)疗法对76例确诊为原发性睑痉挛患者的疗效。肉毒杆菌毒素几乎能缓解所有原发性睑痉挛患者的症状,然而,这种缓解通常是暂时的。重复治疗的起效时间往往比首次治疗更长。轻度睑痉挛患者对肉毒杆菌毒素注射的反应时间明显长于重度痉挛患者。患有Meige综合征的患者对肉毒杆菌毒素的反应与仅患有原发性睑痉挛的患者相比无显著差异。先前接受过原发性睑痉挛手术治疗的患者与未接受过手术治疗的患者反应无差异。作者认为,肉毒杆菌毒素注射是治疗这种局限性肌张力障碍体征和症状的一种有效但暂时的治疗方式。作者认识到可能存在影响反应的心理因素。